Concepedia

Jodi A. McKenzie

JA

Statistics

Publications

27

Citations

3.6K

H-Index

20

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Eisai (United States)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Eisai (United Kingdom)

Jodi A. McKenzie is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2010–2024

27

Publications

27

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Weiyi Peng, Jie Qing Chen, Chengwen Liu et al. · Cancer Discovery · 2015 · 1.5K citations · Full text

Medicine, Immunology, Oncology +17

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

Tina Cascone, Jodi A. McKenzie, Rina M. Mbofung et al. · Cell Metabolism · 2018 · 624 citations · Full text

Medicine, Cancer Biology, Oncology +14

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 163 citations · Full text

Medicine, Oncology, Pharmacology +10

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

Rina M. Mbofung, Jodi A. McKenzie, Shruti Malu et al. · Nature Communications · 2017 · 156 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 27